By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Allele Biotech on Friday announced that it has signed a contract with the National Cancer Institute to conduct RNAi screening aimed at identifying synthetic targets for killing cancer cells.

The San Diego-based firm will use its high-quality fluorescent proteins, lentivirus systems, and shRNA platform for the project. It noted that the University of Florida is a sub-contractor on the contract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.